Literature DB >> 14585409

Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Charles Cha1, Yuman Fong, William R Jarnagin, Leslie H Blumgart, Ronald P DeMatteo.   

Abstract

BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) who undergo complete tumor resection subsequently develop tumor recurrence. The objectives of this study were to determine the risk factors for recurrence of HCC after hepatectomy and to examine the outcomes once tumor recurrence occurs. STUDY
DESIGN: From February 1990 to May 2001 a total of 164 patients underwent liver resection for HCC at our institution and were prospectively followed. Time to recurrence and survival after recurrence were determined by Kaplan-Meier analysis. Patient, tumor, and treatment characteristics were tested for their prognostic significance by univariate and multivariate analysis using the logrank test and the Cox proportional hazards model, respectively.
RESULTS: The median patient age was 64 years (range 21 to 87 years) and 106 patients (65%) were male. After a median followup of 26 months, 90 patients (55%) have developed recurrent cancer. Among them, 75 patients (83%) had tumor detectable in the liver, which was the only site of disease in 67 (74%). In all, 15 patients (20%) had extrahepatic disease (7 lung, 4 peritoneum, 2 pancreas, 1 bone, and 1 brain). The median time to recurrence was 24 months (range 1 to 274 months). Predictors of recurrence on univariate analysis were tumor size greater than 5 cm, more than one tumor, cirrhosis, vascular invasion (microscopic or macroscopic), and tumor satellites. On multivariate analysis only tumor size greater than 5 cm (p = 0.04) and vascular invasion (p = 0.01) predicted recurrence. The median survival after recurrence was 11 months (range 0 to 60 months). Of the 90 patients who developed tumor recurrence 49 (67%) were able to undergo additional ablative or surgical therapy (33 embolization, 9 ethanol injection, and 14 re-resection). On multivariate analysis vascular invasion in the original tumor predicted poor survival after recurrence (p = 0.009).
CONCLUSIONS: The liver is the predominant site of first recurrence after resection of hepatocellular carcinoma, and once recurrence occurs survival is limited. The current study underscores the need for effective adjuvant therapy for patients with HCC treated with partial hepatectomy.

Entities:  

Mesh:

Year:  2003        PMID: 14585409     DOI: 10.1016/j.jamcollsurg.2003.07.003

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  91 in total

1.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

Authors:  Fidel-David Huitzil-Melendez; Marinela Capanu; Eileen M O'Reilly; Austin Duffy; Bolorsukh Gansukh; Leonard L Saltz; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment.

Authors:  Hyojin Kim; Hyunchul Rhim; Dongil Choi; Hyo K Lim; Young-Sun Kim; Won Jae Lee; Jae Won Joh
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

3.  Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma.

Authors:  Victor Zaydfudim; Rory L Smoot; Clancy J Clark; Michael L Kendrick; Florencia G Que; Michael B Farnell; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

Review 4.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

5.  Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jia Fan; Jian Zhou; Zhi-Quan Wu; Shuang-Jian Qiu; Xiao-Ying Wang; Ying-Hong Shi; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

6.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

7.  Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma.

Authors:  Christopher J Sonnenday; Justin B Dimick; Richard D Schulick; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2007-10-03       Impact factor: 3.452

8.  Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.

Authors:  Jia-Zhou Ye; Yong-Quan Zhang; Hai-Hong Ye; Tao Bai; Liang Ma; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study.

Authors:  Zheng-Gang Ren; Zhi-Ying Lin; Jing-Lin Xia; Sheng-Long Ye; Zeng-Chen Ma; Qing-Hai Ye; Lun-Xiu Qin; Zhi-Quan Wu; Jia Fan; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

10.  The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Xiao Xu; Qing-Hong Ke; Zhe-Xin Shao; Jian Wu; Jun Chen; Lin Zhou; Shu-Sen Zheng
Journal:  Dig Dis Sci       Date:  2008-06-18       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.